High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

Inclusion Criteria

• •1. Biopsy-proven metastatic clear cell RCC.
• •2. Radiographic evidence of metastatic disease. 2.1 Patients with any number of metastatic site are allowed to enroll. However, only up to six sites will be selected for SBRT treatment, at the discretion of the treating radiation oncologist.
• •3. Patient must have ≥1 lesion of size \>1.5cm.
• •4. Previous treatment with surgery, radiation, chemotherapy, immunotherapy or any targeted agents are allowed 28 days before the start of HD IL-2
• •5. Age ≥ 18 years.
• •6. Performance status ECOG 0, 1.
• •7. Patient must be eligible for HD IL-2 treatment
• •8. Patient must be eligible for SABR to one or more extra cranial sites.
• •9. Adequate organ and marrow function as defined below:
• •* leukocytes ≥ 3,000/mcL
• •* absolute neutrophil count ≥ 1,500/mcL
• •* platelets ≥ 50,000/mcl
• •* total bilirubin ≤ 2mg/dL
• •* AST(SGOT)/ALT(SPGT) ≤ 2.5 X institutional upper limit of normal
• •10. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• •10.1 A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
• •* Has not undergone a hysterectomy or bilateral oophorectomy; or
• •* Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
• •11. Ability to understand and the willingness to sign a written informed consent
• •12. Adequate Renal function with Cr ≤ 1.6 mg/dL.
• •13. Adequate cardiac function (adequate perfusion; no ischemia) on thallium (or Tc) stress test
• •14. Adequate pulmonary function on PFT (FEV1 \>65%; DLCO\>60%).